Cerebral Venous Thrombosis and COVID-19 Infection in a Patient With Sickle Cell Disease: A Case Report
Background: The most common symptom of the novel Coronavirus Disease 2019 (COVID-19) infection is fever and dyspnea that leads to hypoxia in severe cases. Some COVID-19 patients experience neurological symptoms, including ischemic stroke and intracerebral hemorrhage. Sickle Cell Disease (SCD) is a hypercoagulable state, however, it has not been approved as a significant cause of Cerebral Venous Thrombosis (CVT).
Case presentation: In this case report, we described CVT in an SCD patient who had COVID-19, as well. We reported a 32-year-old man with a history of sickle cell anemia presented with left hemiparesis, headache, and seizure. After evaluation of the patient, CVT accompanied by COVID-19 infection was diagnosed. He was treated with intravenous unsaturated heparin, antiepileptic drugs, and antiviral agents with a favorable outcome. Based on our knowledge, this is the first case study to describe an association between CVT and COVID-19 infection in a patient with SCD.
Conclusion: During the recent pandemic, vaso-occlusive attacks in SCD patients can be evaluated for COVID-19 as an etiological factor.
 Farooq S, Testai FD. Neurologic complicatons of sickle cell disease. Current Neurology and Neuroscience Reports. 2019; 19(4):1-8. [DOI:10.1007/s11910-019-0932-0] [PMID]
 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patents with pneumonia in China, 2019. New England Journal of Medicine. 2020; 20:382-8. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
 Center for Disease Control Preventon. First travel-related case of 2019 novel coronavirus detected in United States [Internet]. 2020 [Updated 2020 January 21]. Available from: htps://www.cdc.gov/ media/releases/2020/p0121-novel coronavirus-travel-case.html
 Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristcs of coronavirus disease 2019 (COVID-19). Journal of General Internal Medicine. 2020; 35(5):1545-9. [DOI:10.1007/ s11606-020-05762-w] [PMID] [PMCID]
 Sharif-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causatve or coincidental? New Microbes and New Infectons. 2020; 35:100669. [DOI:10.1016/j.nmni.2020.100669.] [PMID] [PMCID]
 Karimi N, Sharif Razavi A, Rouhani Nima. Frequent convulsive seizures in an adult patent with COVID-19: A case report. Iranian Red Crescent Medical Journal. 2020; 22(3):102828. [DOI:10.5812/ ircmj.102828]
 Zhai P, Ding Y, Li Y. The impact of COVID-19 on ischemic stroke. Diagnostc Pathology. 2020; 15(1):1-5. [DOI:10.21203/rs.3.rs-20393/v1]
 Sedagha Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infecton: A case report. Journal of Clinical Neuroscience 2020; 76:233-5. [DOI:10.1016/j.jocn.2020.04.062] [PMID] [PMCID]
 Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestatons of hospitalized patents with COVID-19 in Wuhan, China: A retrospectve case series study. SSRN Electronic Journal. 2020. [DOI:10.2139/ssrn.3544840]
 Giannis D, Ziogas IA, Gianni P. Coagulaton disorders in coronavirus infected patents: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. Journal of Clinical Virology 2020; 127:104362. [DOI:10.1016/j.jcv.2020.104362] [PMID] [PMCID]
 DeBaun MR. Initatng adjunct low-dose hydroxyurea therapy for stroke preventon in children with SCA during the COVID-19 pandemic. Blood, the Journal of the American Society of Hematology. 2020; 135(22):1997-9. [DOI:10.1182/blood.2020005992] [PMID] [PMCID]
|Issue||Vol 5 No Covid- 19 (2020): In Press|
|COVID-19 Coronavirus Cerebral venous thrombosis Sickle cell disease|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|